Osteoporosis in COPD

European Respiratory Monograph

Volumn 59, Issue , 2013, Pages 93-104

  Romme, Elisabeth A M P ^a   Smeenk, Frank W J M ^a   Wouters, Emiel F M ^b   Rutten, Erica P A ^c  

^a CATHARINA HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Centre of Expertise for Chronic Organ Failure (CIRO)   (Netherlands)

Author keywords

Bone density; Comorbidity; COPD; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; DENOSUMAB; FLUTICASONE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; TUMOR NECROSIS FACTOR ALPHA;

AGING; AIRWAY OBSTRUCTION; ALCOHOL CONSUMPTION; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE MASS; BONE REMODELING; CALCIUM ABSORPTION; CALCIUM EXCRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EMPHYSEMA; FAT MASS; FRACTURE; FRAGILITY FRACTURE; HOARSENESS; HUMAN; IMMOBILIZATION; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY DYSFUNCTION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OROPHARYNX CANDIDIASIS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PANCREATIC STELLATE CELL; PATHOPHYSIOLOGY; PNEUMONIA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW (TOPIC); VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84874854250     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10011712     Document Type: Article

References (87)

1. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest 2011; 139: 648-657.
2. WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: report of a WHO scientific group. WHO technical report series; 920. Geneva, World Health Organisation, 2003.
3. Lyles KW, Gold DT, Shipp KM, et al. Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 1993; 94: 595-601.
4. Myers AH, Robinson EG, Van Natta ML, et al Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol 1991; 134: 1128-1137.
5. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008; 43: 1115-1121.
6. Papaioannou A, Parkinson W, Ferko N, et al. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 2003; 14: 913-917.
7. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
8. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-1148.
9. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136: 1456-1465.
10. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009; 201: 309-320.
11. Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 2011; 26: 561-568.
12. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-1293.
13. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
14. Papaioannou A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int 2009; 20: 507-518.
15. Waugh EJ, Lam MA, Hawker GA, et al. Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature. Osteoporos Int 2009; 20: 1-21.
16. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
17. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-14.
18. Lekamwasam S, Trivedi DP, Khaw KT. An association between respiratory function and bone mineral density in women from the general community: a cross sectional study. Osteoporos Int 2002; 13: 710-715.
19. Silva DR, Coelho AC, Dumke A, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care 2011; 56: 961-968.
20. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009; 34: 209-218.
21. Coin A, Sergi G, Marin S, et al. Predictors of low bone mineral density in elderly males with chronic obstructive pulmonary disease: the role of body mass index. Aging Male 2010; 13: 142-147.
22. Graat-Verboom L, Spruit MA, van den Borne BE, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med 2009; 103: 1143-1151.
23. Bon J. Does radiographic emphysema correlate with low bone mineral density? Curr Opin Pulm Med 2012; 18: 125-130.
24. Engelen MP, Schols AM, Lamers RJ, et al. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999; 18: 275-280.
25. Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobaccoexposed cohort. Am J Respir Crit Care Med 2011; 183: 885-890.
26. Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008; 134: 1244-1249.
27. Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res 2011; 12: 157.
28. Kneidinger N, Yildirim AO, Callegari J, et al. Activation of the WNT/beta-catenin pathway attenuates experimental emphysema. Am J Respir Crit Care Med 2011; 183: 723-733.
29. Afonso AS, Verhamme KM, Sturkenboom MC, et al. COPD in the general population: prevalence, incidence and survival. Respir Med 2011; 105: 1872-1884.
30. Faner R, Rojas M, MacNee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 306-313.
31. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005; 29: 23-32.
32. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 566-571.
33. Lee J, Sandford A, Man P, et al. Is the aging process accelerated in chronic obstructive pulmonary disease? Curr Opin Pulm Med 2011; 17: 90-97.
34. Syed FA, Ng AC. The pathophysiology of the aging skeleton. Curr Osteoporos Rep 2010; 8: 235-240.
35. Sturnieks DL, St George R, Lord SR. Balance disorders in the elderly. Neurophysiol Clin 2008; 38: 467-478.
36. Nguyen ND, Pongchaiyakul C, Center JR, et al. Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 2005; 20: 1921-1928.
37. Schols AM, Mostert R, Soeters PB, et al. Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991; 46: 695-699.
38. Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94: 859-867.
39. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173: 79-83.
40. Bolton CE, Cannings-John R, Edwards PH, et al. What community measurements can be used to predict bone disease in patients with COPD? Respir Med 2008; 102: 651-657.
41. Cavanagh PR, Licata AA, Rice AJ. Exercise and pharmacological countermeasures for bone loss during longduration space flight. Gravit Space Biol Bull 2005; 18: 39-58.
42. LeBlanc AD, Schneider VS, Evans HJ, et al. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 1990; 5: 843-850.
43. Takata S, Yasui N. Disuse osteoporosis. J Med Invest 2001; 48: 147-156.
44. Reid IR. Fat and bone. Arch Biochem Biophys 2010; 503: 20-27.
45. Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med 2012; 272: 317-329.
46. Pobeha P, Ukropec J, Skyba P, et al. Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. Bone 2011; 48: 1008-1014.
47. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD002991.
48. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787.
49. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899.
50. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 704-709.
51. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56: 279-284.
52. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 855-859.
53. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
54. Lafage-Proust MH, Boudignon B, Thomas T. Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 2003; 70: 109-118.
55. Goldstein MF, Fallon JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999; 116: 1733-1749.
56. Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med 2012 [Epub ahead of print DOI: 10.3109/07853890.2012.671536].
57. Persson LJ, Aanerud M, Hiemstra PS, et al. Chronic obstructive pulmonary disease is associated with low levels of vitamin D. PLoS One 2012; 7: e38934.
58. Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010; 65: 215-220.
59. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
60. Dirks-Naylor AJ, Lennon-Edwards S. The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol 2011; 125: 159-168.
61. Forli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 2004; 256: 56-62.
62. Vorrink SN, Kort HS, Troosters T, et al. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 33.
63. Marie PJ, Kassem M. Extrinsic mechanisms involved in age-related defective bone formation. J Clin Endocrinol Metab 2011; 96: 600-609.
64. Pluijm SM, Koes B, de Laet C, et al. A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res 2009; 24: 768-774.
65. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; 7: CD000333.
66. de Kam D, Smulders E, Weerdesteyn V, et al. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int 2009; 20: 2111-2125.
67. Nishimura Y, Nakata H, Tsutsumi M, et al. Relationship between changes of bone mineral content and twelveminute walking distance in men with chronic obstructive pulmonary disease: a longitudinal study. Intern Med 1997; 36: 450-453.
68. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68: 259-270.
69. Hirayama F, Lee AH, Binns CW, et al. Alcohol consumption in patients with chronic obstructive pulmonary disease in Japan. Asia Pac J Public Health 2008; 20: Suppl, 87-94.
70. Fini M, Salamanna F, Veronesi F, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed) 2012; 4: 2686-2706.
71. Maurel DB, Boisseau N, Benhamou CL, et al. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int 2012; 23: 1-16.
72. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int 2012; 23: 2081-2092.
73. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-666.
74. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a metaanalysis of randomized controlled trials. JAMA 2005; 293: 2257-2264.
75. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005; 3: CD000227.
76. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.
77. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339: b3692.
78. van den Bergh JP, Bours SP, van Geel TA, et al. Optimal use of vitamin D when treating osteoporosis. Curr Osteoporos Rep 2011; 9: 36-42.
79. Reid IR, Bolland MJ, Sambrook PN, et al. Calcium supplementation: balancing the cardiovascular risks. Maturitas 2011; 69: 289-295.
80. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-474.
81. Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001; 12: Suppl. 3, S3-S10.
82. Smith BJ, Laslett LL, Pile KD, et al. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis 2004; 1: 131-137.
83. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012; 97: 1871-1880.
84. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.
85. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
86. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
87. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-1526.